ArticleJournal of pain research2026
Effects of Intravenous Lidocaine on Rheumatoid Arthritis in Preclinical Rat Model and Clinical Trial.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is characterized by chronic synovial inflammation and pain. Lidocaine has anti-inflammation and pain-relieving properties. This study intends to evaluate the effects of lidocaine on RA in a preclinical rat model and a clinical trial. Methods: Rats with adjuvant-induced arthritis (AIA) received intravenous lidocaine or no treatment. Pain behavior parameters and arthritis index (AI) were assessed. Synovial tissue lesions, the number of M1 macrophages and gene expression of inflammatory molecules: IKKα, NF-κB p65, IL-1β and TNF-α were profiled by immunohistochemical staining or quantitative PCR. In clinical trial, RA patients (n=40) were assigned into two groups: control group received conventional treatments, lidocaine group: received conventional treatment and intravenous lidocaine for 5 days. Visual analogue scale score (VAS), disease activity score 28 (DAS28) and temperature in painful joint area were recorded. Results: Lidocaine-treated rats had significantly lower pain parameters, synovial pathology and AI scores, M1 macrophages and gene expressions of inflammatory molecules in synovial tissues on day 28 post modeling compared to AIA rats without the treatment. In a clinical trial, patients who received intravenous lidocaine had similar VAS, DAS28 and SDAI scores in comparison with patients without the treatment. However, lidocaine-treated patients had significantly lower temperatures in the painful joint areas and dosages of glucocorticoids and nonsteroidal anti-inflammatory drugs during the treatment period, compared to patients without intravenous lidocaine. Conclusion: Intravenous lidocaine attenuated joint pain and synovial inflammation in preclinical AIA rat model and provided adjunctive beneficial effects for the treatment of RA patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.